Seattle Rheumatology Associates, Seattle, WA 98104, USA. pmease @ nwlink.com
Dermatology. 2010;220(1):1-7. doi: 10.1159/000260371. Epub 2009 Nov 19.
Psoriatic arthritis often affects patients with psoriasis.
To examine the effect of adalimumab on psoriatic arthritis in patients with moderate to severe psoriasis.
Data from patients with psoriasis and a reported history of comorbid psoriatic arthritis in 3 randomized, placebo-controlled psoriasis trials of adalimumab were analyzed.
Adalimumab (n = 274) reduced the risk of psoriatic arthropathy adverse events by 75% versus placebo (1.1 vs. 4.8%; p = 0.025). Psoriasis/psoriatic arthritis-related pain was significantly reduced (-31.3 vs. -5.6 visual analog scale units; p < 0.0001). At week 16, adalimumab-treated patients were more likely to respond (56.9 vs. 4.5%; p < 0.001) and responded for a greater percentage of follow-up time (39.3 vs. 2.9%; p< 0.0001) than placebo-treated patients (regression model for PASI 75 and ACR 20 responses).
Adalimumab treatment of moderate to severe psoriasis reduced symptoms of comorbid psoriatic arthritis.
银屑病关节炎常影响银屑病患者。
观察阿达木单抗对中重度银屑病患者合并的银屑病关节炎的疗效。
对阿达木单抗治疗银屑病的 3 项随机、安慰剂对照临床试验中，有合并银屑病关节炎报告病史的银屑病患者的数据进行分析。
与安慰剂相比，阿达木单抗（n = 274）降低了 75%的银屑病关节炎不良事件风险（1.1%比 4.8%；p = 0.025）。银屑病/银屑病关节炎相关疼痛显著减轻（-31.3 比-5.6 视觉模拟量表单位；p < 0.0001）。在第 16 周，阿达木单抗治疗组患者更有可能应答（56.9%比 4.5%；p < 0.001），且在随访时间内应答比例更高（39.3%比 2.9%；p< 0.0001），优于安慰剂治疗组（PASI75 和 ACR20 应答的回归模型）。
阿达木单抗治疗中重度银屑病可减轻合并的银屑病关节炎的症状。
